Source: 12 Month DayTwo National Book of Business Outcomes, March 2022. Note: A1C, TIR, and weight loss reflect averages.
Medication reduction and quality of life measures reflect percentage of members who reported change.1
Source: 12 Month DayTwo National Book of Business Outcomes, March 2022. Note: Individual results may vary.
See the difference of Time-in-Range before DayTwo and the improvement that happens when we help individuals make personalized tweaks to their diet.
Time in Range
Hemoglobin A1c (A1C) became the gold standard for blood sugar management after the Diabetes Control and Complications Trial (DCCT) demonstrated the strong association between A1C levels and the risk of chronic vascular complications. Although its important role in diabetes management as a clinical trial outcome and as a predictor of long-term diabetic complications cannot be overstated, A1C does have certain limitations. A1C is an average of blood sugar measurements over 2 to 3 months.
But with the advent of continuous blood glucose monitors (CGM), daily fluctuations can be detected in blood glucose levels.
Time in Range (TIR) is the percentage of time in which blood glucose levels remain in a target range. American Diabetes Association (ADA) guidelines suggest a range of 70 to 180 mg/dl.
TIR captures the highs, lows, and in-range values that characterize daily life with diabetes. Thinking about blood glucose in terms of TIR offers a more precise understanding of diabetes. You can see how specific foods, behaviors, or exercise affect your TIR.
Time in Range is Correlated with Complications
Studies suggest that TIR can effectively predict long-term diabetes complications (Diabetes Care 2019, Diabetes Care 2018) such as eye disease (retinopathy) and kidney disease (microalbuminuria). As Time in Range increased, complications decreased.
TIR and other blood sugar metrics—especially when measured with continuous glucose monitoring—add value as outcome measures in many studies.
Time in Range between 70 and 180 mg/dl is the healthy range for members with diabetes.
Our innovation allows people to normalize their blood sugar using their own body’s wisdom, without more meds or costly & invasive interventions. This is vital for diabetes care.
Note: This graph is a simulation of the type of improvement DayTwo's diabetes management program could enable. Individual results may vary.
The Microbiome Platform Is Coming
This is vital for diabetes care. Our innovation allows people for the first time to normalize their own blood sugar using their own body’s wisdom and without more meds or costly & invasive interventions.
Source: 12 Month DayTwo National Book of Business Outcomes, March 2022.
When you have a program built around individual biology vs. restrictive diets, people are more likely to stick with it— and stay healthy.
Citation and Footnotes